Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female aged \> 18 years.~* Patients with operable breast cancer, with measurable tumors of more than 1 cm in diameter, that are not candidates for neoadjuvant therapy.~* Zubrod (Eastern Co-operative Oncology Group \[ECOG\]) Performance Status (PS) of 0-1.~* No prior treatment by surgery, radiotherapy, hormone therapy e.g. TAMOXIFEN® or RALOXIFEN® for prevention or chemotherapy.~* Scheduled to undergo definitive local surgery for breast cancer.~* Patients must be willing to undergo two mandatory tumor biopsies (pre and post therapy) that are not required for standard care. A sample of tumor tissue removed during surgery will also be collected for analysis.~* Patients must be able to swallow and retain oral medication (intact tablet).~* Able to undergo all screening assessments outlined in the protocol after giving informed consent.~* Adequate organ function (defined by the following parameters):~  1. Serum creatinine \< 140 μmol/L or creatinine clearance \> 60 mL/min.~ 2. Serum hemoglobin \> 9 g/dL; absolute neutrophil count \> 1.5 x 109/L; platelets \> 100 x 109/L.~ 3. Serum bilirubin \< upper normal limit (UNL).~ 4. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ UNL; alkaline phosphatase (ALP) ≤ UNL; albumin within normal limits.~* Documented hormone receptor (ER and progesterone receptor) and HER-2- status.~* No known hepatitis B virus (unless due to immunization), hepatitis C virus, human immune deficiency virus-I and II positive status.~Exclusion Criteria:~* Male.~* Pregnancy or lactation or unwillingness to use two adequate methods of birth control throughout the study and for 30 days after study discontinuation.~* Any other breast cancer types including inflammatory form.~* Prior surgery to the breast area or primary axillary dissection.~* Prior treatment for breast cancer.~* Use of an investigational drug within 30 days preceding the first dose of study medication.~* Any prior or current cancer, except in situ uterine carcinoma or basocellular cutaneous cancer considered as definitively cured.~* Any associated medical condition considered incompatible with the study, e.g. cardiac, renal, medullar, respiratory or hepatic insufficiency.~* Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures.~* Active or uncontrolled infection.~* Malabsorption syndrome, disease significantly affecting gastrointestinal function.~* Hypersensitivity to:~  1. ibuprofen or to more than one non-steroidal anti-inflammatory drug;~ 2. medications belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treated patients - Total (Type: EXPERIMENTAL): Patients eligible will be treated with Reparixin as add-in monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues